Childhood Solid Tumor
13
3
4
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
23.1%
3 terminated out of 13 trials
62.5%
-24.0% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
French Childhood Cancer Survivor Study
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Precision Medicine for Every Child With Cancer
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
PRecISion Medicine for Children With Cancer
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours